08/08/2025
CanWell will Present Latest ADC Program Updates at 16th World ADC in San Diego, CA (Nov 3-6, 2025)
CanWell Pharma will present it…
CanWell will Present Clinical Updates on an IFN-α Biased TLR7 Agonist CAN1012 at ESMO 2025 – Annual Meeting (October 17-21, 2025)
CanWell Pharma will present la…
CanWell will attend ADC & Novel Conjugates Partnering & Investment Summit (September 9-10, 2025)
CanWell Pharma will update com…
11/04/2024
CanWell Pharma will Present Research Developments at The Society for Immunotherapy of Cancer (SITC) Annual Meeting
CanWell Pharma will present th…
CanWell Pharma will Present Latest Research Developments at World ADC 2024 in San Diego, CA
CanWell Pharma will present it…
10/06/2024
Nature Biopharma Dealmakers Publishes CanWell’s StarLinker ADC conjugation platform
Read More (click to read the o…
04/10/2024
CanWell Pharma’s First-in-Class innovative drug CAN2109 granted IND approval by China National Medical Products Administration (NMPA)
CanWell Pharma announced that …
11/16/2023
CanWell’s CAN2109 IND Granted Approval by US FDA
CanWell Pharma announced that …
05/09/2023
Canwell to Present CAN1012 Research Update at the 4th STING & TLR Targeting Therapies Summit
CanWell announced today that t…
02/12/2023
CanWell was Invited to Present at 9th Immuno-oncology 360° (IO360°) Conference
CanWell presented the preclini…